日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial

基于LDL受体功能的PCSK9抑制剂治疗家族性高胆固醇血症的疗效：一项非随机临床试验

期刊:Jama Cardiology
影响因子:14.1
doi:10.1001/jamacardio.2026.0879
Raal, Frederick J; Fourie, Nyda; Scott, Russell; Blom, Dirk J; Basson, Matthys M De Vries; Kayikcioglu, Meral; Roth, Mendel; Vest, Jeffrey; Kallend, David; Stein, Evan A
PCSK9
信号转导
CSK
代谢
发表日期：2026
文献求助 收藏

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial

利罗达西贝普治疗心血管疾病患者或高危患者的疗效和安全性：一项随机临床试验

期刊:Jama Cardiology
影响因子:14.1
doi:10.1001/jamacardio.2024.1659
Klug, Eric Q; Llerena, Sara; Burgess, Lesley J; Fourie, Nyda; Scott, Russell; Vest, Jeff; Caldwell, Kate; Kallend, David; Stein, Evan A
心血管疾病
心血管
发表日期：2024
文献求助 收藏

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Inclisiran 与心血管事件：III 期试验的患者水平分析

期刊:European Heart Journal
影响因子:35.6
doi:10.1093/eurheartj/ehac594
Ray, Kausik K; Raal, Frederick J; Kallend, David G; Jaros, Mark J; Koenig, Wolfgang; Leiter, Lawrence A; Landmesser, Ulf; Schwartz, Gregory G; Lawrence, David; Friedman, Andrew; Garcia Conde, Lorena; Wright, R Scott
发表日期：2023
文献求助 收藏

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

利罗达西贝治疗杂合子家族性高胆固醇血症的长期疗效和安全性：LIBerate-HeFH试验

期刊:European Heart Journal
影响因子:35.6
doi:10.1093/eurheartj/ehad596
Raal, Frederick; Fourie, Nyda; Scott, Russell; Blom, Dirk; De Vries Basson, Matthys; Kayikcioglu, Meral; Caldwell, Kate; Kallend, David; Stein, Evan
代谢
发表日期：2023
文献求助 收藏

The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions

N-乙酰半乳糖胺结合的小干扰 RNA inclisiran 可安全地与阿托伐他汀在食蟹猴中共同给药，从而降低低密度脂蛋白胆固醇

期刊:Pharmacology Research & Perspectives
影响因子:2.9
doi:10.1002/prp2.1080
Dario Lehoux, David Kallend, Peter L J Wijngaard, Alan P Brown, Brad Zerler
代谢
发表日期：2023
文献求助 收藏

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

英克利西兰对一级预防中血脂的影响：ORION-11试验

期刊:European Heart Journal
影响因子:35.6
doi:10.1093/eurheartj/ehac615
Ray, Kausik K; Kallend, David; Leiter, Lawrence A; Raal, Frederick J; Koenig, Wolfgang; Jaros, Mark J; Schwartz, Gregory G; Landmesser, Ulf; Garcia Conde, Lorena; Wright, R Scott
发表日期：2022
文献求助 收藏

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study.

评估超治疗剂量的inclisiran对健康志愿者心脏复极化的影响：一项 I 期随机研究

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13391
Kallend David, Mason Jay, Smith Patrick F, Koren Michael J, Stoekenbroek Robert, He YanLing, Wijngaard Peter
其它
发表日期：2022
文献求助 收藏

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

达塞曲匹可降低冠心病患者新发糖尿病的风险

期刊:
影响因子:
doi:10.2337/dc19-2204
Schwartz, Gregory G; Leiter, Lawrence A; Ballantyne, Christie M; Barter, Philip J; Black, Donald M; Kallend, David; Laghrissi-Thode, Fouzia; Leitersdorf, Eran; McMurray, John J V; Nicholls, Stephen J; Olsson, Anders G; Preiss, David; Shah, Prediman K; Tardif, Jean-Claude; Kittelson, John
代谢
糖尿病
心血管
冠心病
发表日期：2020
文献求助 收藏

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

剂或 2 剂 Inclisiran 对低密度脂蛋白胆固醇水平的影响：ORION-1 随机临床试验的一年随访

期刊:Jama Cardiology
影响因子:14.1
doi:10.1001/jamacardio.2019.3502
Ray, Kausik K; Stoekenbroek, Robert M; Kallend, David; Nishikido, Toshiyuki; Leiter, Lawrence A; Landmesser, Ulf; Wright, R Scott; Wijngaard, Peter L J; Kastelein, John J P
代谢
发表日期：2019
文献求助 收藏

Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial

脂蛋白(a)与急性冠脉综合征后复发性缺血事件风险的相关性：dal-Outcomes随机临床试验分析

期刊:Jama Cardiology
影响因子:14.1
doi:10.1001/jamacardio.2017.3833
Schwartz, Gregory G; Ballantyne, Christie M; Barter, Philip J; Kallend, David; Leiter, Lawrence A; Leitersdorf, Eran; McMurray, John J V; Nicholls, Stephen J; Olsson, Anders G; Shah, Prediman K; Tardif, Jean-Claude; Kittelson, John
发表日期：2018
文献求助 收藏